勃林格殷格翰宣布启动一项1B期临床研究，旨在评估其创新药物Zongertinib（一种新型酪氨酸激酶抑制剂）与Zanidatamab（一种双特异性HER2靶向抗体）联合用药方案，在HER2阳性乳腺癌患者中的安全性、耐受性及初步疗效。
该研究标志着公司在精准肿瘤治疗领域的重要布局，有望为当前治疗方案有限的HER2阳性乳腺癌患者提供新的治疗选择。研究将重点关注联合疗法的药代动力学特性及生物标志物反应，为后续临床开发提供关键数据支持。
勃林格殷格翰宣布启动一项1B期临床研究，旨在评估其创新药物Zongertinib（一种新型酪氨酸激酶抑制剂）与Zanidatamab（一种双特异性HER2靶向抗体）联合用药方案，在HER2阳性乳腺癌患者中的安全性、耐受性及初步疗效。
该研究标志着公司在精准肿瘤治疗领域的重要布局，有望为当前治疗方案有限的HER2阳性乳腺癌患者提供新的治疗选择。研究将重点关注联合疗法的药代动力学特性及生物标志物反应，为后续临床开发提供关键数据支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.